The product of the c-myc proto-oncogene is a highly conserved yet functionally diverse nuclear protein fundamental to promotion of both cell growth and apoptotic cell death. c-Myc expression is tightly linked to the proliferative potential of the cell; indeed, both c-myc mRNA and protein levels elevate in response to serum or mitogen stimulation (28, 51, 106) . Furthermore, induction of c-Myc expression stimulates quiescent cells to enter the cell cycle and is sufficient to promote G 1 -to-S phase progression (26, 34, 61) . Overexpression of ectopic cMyc renders cells immortal and, in combination with cooperating oncogenes, induces cellular transformation and tumor formation (1, 2, 18, 57, 88, 97) . Moreover, Myc oncogenic activation resulting from deregulated c-myc expression frequently coincides with the tumorigenic phenotype in a wide variety of cell types (reviewed in references 67 and 96). Thus, Myc plays a central and essential role in governing proliferation, and precise regulation of c-myc expression in response to changing intra-and extracellular signals is key to maintaining cell growth control.
A variety of pathways, including transcriptional, posttranscriptional, and translational control mechanisms, cooperate to regulate c-Myc expression in vivo (for reviews, see references 52 and 96) . Both c-myc mRNA and the Myc protein are shortlived molecules with half-lives of approximately 30 min (46, 81, 106) . Transcription initiates from two major promoters within the untranslated first exon, P1 and P2, with the majority of transcripts originating from the latter site. A block to P2 transcription elongation occurs at sequences located in the 3Ј end of exon I, and this attenuation is recognized as an important regulatory process governing Myc expression during terminal differentiation (11, 12, 74) . A perplexing array of proximal and distal regulatory elements positively and negatively influence c-myc transcription initiation to control basal and mitogenresponsive c-myc expression. Interestingly, several of the proteins identified to date which bind to or operate through these elements are themselves oncoproteins or tumor suppressor proteins, including Ets, v-Abl, p53, pRb, and p107 (25, 45, 82, 89, 110) .
Structurally, c-Myc protein possesses several domains characteristic of transcriptional activators, including an amino-terminal activation domain, a carboxyl-terminal basic region (BR) involved in DNA binding, and a contiguous helix-loop-helix and leucine zipper (HLH-Zip) motif responsible for protein dimerization (63, 77) . Indeed, c-Myc interacts in vitro and in vivo with another cellular BR-HLH-Zip protein, Max, forming heterodimers which recognize and bind to the E-box element CACGTG and activate transcription (5, 16, 17, 50, 80) . MycMax interaction is required for several key biological functions of Myc, including G 1 -to-S phase cell cycle progression, apoptosis, and cellular cotransformation (4, 6, 79) . Surprisingly, only a handful of genes have been identified as bona fide cellular targets of Myc-Max transcriptional activation, including ornithine decarboxylase, ECA39, ␣-prothymosin, cad, and p53 (10, 13, 34, 70, 86, 104) .
Recent reports have demonstrated that c-Myc protein also suppresses transcription initiation from specific promoters. Overexpression of c-Myc in 3T3-L1 cells suppresses CTF/NF-1-dependent promoters via phosphorylation of the CTF/NF-1 transcription factor (111) . c-Myc expression can also lead to suppression of c-neu, LFA-1, and major histocompatibility complex type I cellular promoters (49, 98, 103) , but whether this occurs via direct or indirect pathways has not been established. High concentrations of Myc protein suppress a number of promoters through transcription initiator elements, including the adenovirus major late promoter (AdMLP) and the c/EBP␣, albumin, cyclin D1, terminal deoxynucleotidyltransferase (TdT), and 5 promoters (58, 65, 78) . Moreover, in vitro studies have shown that Myc can be detected in complexes at initiators of the latter three promoters and can interact with two initiator-binding proteins, TFII-I and YY-1 (65, 90, 94) . Conflicting data surround the regions of the Myc protein required for this downregulation. Cyclin D1 promoter suppression involves a distinct region of the Myc amino terminus which does not correlate with Myc cotransformation activity (78) . However, amino-terminal domains required for suppression of the AdMLP coincide with cotransformation domains and are uncoupled from those required for transcription activation, reminiscent of the E1A transformation mechanism. Despite the important biological role for Myc downregulation of gene transcription (58) , the exact mechanism(s) of Myc transcriptional suppression are unknown and the role of MycMax interactions in these mechanisms is unclear or has not been addressed.
We and others have previously demonstrated that the Myc protein suppresses transcription initiation from the c-myc promoter in a concentration-dependent manner (24, 41, 75, 76) . Myc negative autoregulation is a homeostatic control mechanism which is operative in primary and immortalized but not tumor-derived or transformed cell lines (36, 41, 75) . The c-Myc protein domains required for autosuppression overlap those necessary for Myc oncogenic and apoptotic activities. These regions include amino acids 106 to 143, containing the highly conserved Myc box II (MbII) sequence, as well as carboxylterminal BR-HLH-Zip motifs (35, 76, 97) . Furthermore, loss of Myc negative autoregulation is one mechanism contributing to c-myc oncogenic activation (36) , illustrating the biological importance of this feedback pathway.
The molecular mechanism of Myc autosuppression is unknown; however, we have shown that disruption of this negative-autoregulation pathway may result from dysfunction of uncharacterized cis-acting and trans-acting cellular components (36, 75) . To examine the cis elements involved, a search for Myc-Max heterodimer interaction on the Xenopus c-myc I locus was conducted but failed to detect protein binding, thus leaving the mechanism of Myc autosuppression unresolved (20) . Others have postulated that Myc autosuppression may operate through c-Myc inhibition of the activity of YY-1, a transcription factor involved in upregulation of c-myc P1 and P2 transcription (87, 94) . Alternative results implicate a role for the c-myc promoter and specifically for the TCTCTTA positive control element 1.4 kb upstream of the P1 promoter (54) or for the nearby CTF/NF-1 sites (62, 111) . These conflicting results may reflect differences in the assays and cell types used in the various studies. Indeed, the physiological significance of most of these previous reports is unclear, as results from c-myc promoter assays were not verified by direct comparison with Myc autosuppression of the endogenous cmyc gene (36, 41) .
Delineating the mechanism of Myc as a transcriptional regulator is essential to understand the key role of Myc in controlling cellular proliferation. Using the Myc negative autoregulation pathway as a model system, we further investigated the mechanism by which Myc can suppress transcription initiation in a physiologically relevant setting. To investigate the cis components of Myc autosuppression in detail, we examined regulation of c-myc promoter-luciferase reporter constructs in response to conditional and constitutive Myc activation in the autosuppression-competent Rat-1 cell line. We demonstrated specific suppression of a P2 minimal promoter fragment by Myc activation. Furthermore, we clearly established that this promoter fragment response mimics suppression by Myc of the endogenous c-myc gene. In addition, we investigated the nature of the trans cellular components essential to Myc negative autoregulation and demonstrated an obligatory requirement for Myc and Max association in this feedback mechanism.
MATERIALS AND METHODS
Cell lines and culture conditions. The Rat-1, Rat-1 MycER, and ⌬MycER cell lines and the Rat-1 cell lines stably expressing human c-Myc protein mutants have already been described (26, 35, 75, 76) . NIH 3T3-10 is a subclone of the NIH 3T3 cell line described by Penn et al. (75) . The GPϩE packaging cell line (69) was used for infectious, replication-deficient, ecotropic retrovirus production. Rat-1, NIH 3T3-10, and GPϩE cells were cultured in ␣-modified Eagle's medium (␣-MEM) supplemented with 10% fetal bovine serum (GIBCO). Rat-1 MycER and ⌬MycER cells were routinely passaged in phenol red-negative (PR Ϫ ) ␣-MEM supplemented with 10% charcoal-treated serum (CTS; Hyclone). All media were supplemented with 100 g of kanamycin per ml and 2 g gentamicin per ml. All cell lines were incubated at 37ЊC in 5% CO 2 and tested negative for Mycoplasma infection. Photomicrographs of cell lines were taken with a phase-contrast microscope (Nikon) and Polaroid 667 film.
Plasmids and vectors. To generate c-myc promoter-luciferase reporter constructs, a 2.5-kb HindIII-BamHI c-myc fragment was subcloned from the HBmyc-CAT reporter construct (kind gift of E. Laufer) into pBluescript (Stratagene). This fragment was excised from pBluescript by KpnI-SacI partial digestion and subcloned into the pGL2-basic reporter plasmid (Promega) to generate HBMLuc. SNM-Luc was constructed by subcloning the 502-bp ScaI-BamHI fragment from HBMyc-CAT into the SmaI-BglII sites of pGL2-basic. XNM-Luc was constructed by subcloning the 142-bp XhoI-BamHI fragment from HBMyc-CAT into the XhoI-BglII sites of pGL2-basic. The pgagneoSRV and pDoK v-myc retroviral constructs have been previously described (72, 75) . The pBabe Myc puro, pBabe MycEG puro, pBabe Max hygro, and pBabe MaxEG hygro retroviral vectors were the kind gift of B. Amati and are derived from the myceg and maxeg expression constructs described by Amati et al. (4) .
Site-directed mutagenesis. Mutagenesis of the XNM-Luc plasmid was performed in situ based on the method of Deng and Nickoloff (29) by using the Transformer Site-Directed Mutagenesis Kit (Clontech) in accordance with the manufacturer's instructions. The oligonucleotides used to produce nucleotide substitutions within the c-myc promoter were as follows: ⌬ME1a1-1, 5Ј-GGAA AAAGAACGGATGTAGGGATCGCG-3Ј; ⌬ME1a1-2, 5Ј-GAACGGAGGGA TGTATCGCGCTGAG-3Ј; ⌬E2, 5Ј-CAGAGGCTTGGTTTCAAAAAGAACG GAGGG-3Ј; ⌬MBP-1, 5Ј-GGGATCGCGCTTAGTATAAAAGCC-3Ј; ⌬MInr-B-1, 5Ј-CGGGGCTTTATCAGACTCGCTGTAG-3Ј; ⌬MInr-B-2, 5Ј-GGGGCT TTATCTAACAGACTGTAGTAATTCCAG-3Ј; ⌬MInr-A-1, 5Ј-GCTGTAGA GATTCCAGCGAGAGGCAG-3Ј; ⌬MInr-A-2, 5Ј-CTCGCTGTAGTAATAG GAGCGAGAGGCAGAG-3Ј. The selection primer used to enrich for mutant plasmids was 5Ј-CATGTCTGGGCCCGTCGACC-3Ј, which converts a unique BamHI site in the vector to an ApaI site. Briefly, the selection primer and an excess of one mutagenic primer were simultaneously annealed to denatured single-stranded XNM-Luc plasmid DNA. After elongation and ligation to generate the mutant strand, parental plasmid DNA was selected against by digestion with BamHI. The hybrid plasmid was electroporated into repair-deficient BMH 71-18 mutS cells, amplified, and isolated by alkaline lysis. Once again, parental plasmid DNA was selectively eliminated by BamHI digestion. Mutated plasmid DNA was transformed into DH5␣ cells and isolated by alkaline lysis, and mutations were confirmed by restriction enzyme digestion and direct nucleotide sequencing (Pharmacia).
Transient transfections. All cell lines were transfected by the calcium phosphate precipitation method (40) . Rat-1 MycER or Rat-1 ⌬MycER cells were seeded in 60-mm-diameter tissue culture dishes (Nunc) at approximately 40 to 50% confluence in PR Ϫ ␣-MEM-10% CTS and allowed to grow overnight. To enhance transfection efficiency, the medium was switched on the following day to phenol red-positive PR ϩ ␣-MEM supplemented with 10% Cool Calf II serum (Sigma) 0.5 h prior to transfection. A total of 10 g of DNA was added to each plate: 3 g of c-myc promoter-luciferase reporter plasmid DNA plus 0.1 g of pCMV-␤gal (kind gift of T. Lee and E. Ziff) plus 6.9 g of pBluescript (Stratagene). Following incubation at 37ЊC in 5% CO 2 for 6 h, cells were washed twice with prewarmed phosphate-buffered saline (PBS), replenished with fresh PR ϩ ␣-MEM-10% Cool Calf II serum, and incubated overnight to allow recovery. On the next day, cells were again washed twice with prewarmed PBS and placed in PR Ϫ ␣-MEM-10% CTS. Control cells were left untreated, and MycER or ⌬MycER was induced in the remaining cells by addition of the appropriate concentration of 4-hydroxytamoxifen (OH-T) (E or Z isoform; Research Biochemicals) or ␤-estradiol (Sigma) dissolved in 100% ethanol. Cells were harvested 24 h later, and luciferase and ␤-galactosidase activities were assayed. All samples were assayed in triplicate, and all experiments were performed two to five times.
Luciferase and ␤-galactosidase assays. At the time of harvesting, cells were placed on ice, washed with ice-cold PBS, and scraped into 1.5-ml Eppendorf tubes in 1 ml of cold PBS. Cells were centrifuged at 4,000 ϫ g for 2 min, and pellets were lysed in 100 l of lysis buffer (100 mM KH 2 Retroviral transfections, infections, and selections. Retroviral vector DNA was transfected into the GPϩE packaging cell line by the calcium phosphate precipitation method (40) . High-titer supernatant containing retrovirus was harvested from pooled, drug-resistant colonies and used to infect Rat-1 fibroblasts by the method of Mann et al. (66) . Selection of fibroblasts was conducted at the following concentrations: GPϩE, 2 g of puromycin per ml; 100 g of hygromycin B sulfate per ml; NIH 3T3-10, 1 mg of G418 sulfate per ml; Rat-1, 2 to 2.5 g of puromycin per ml plus 150 g of hygromycin B sulfate per ml.
Rat-1 cells were infected with either a replication-deficient control retrovirus carrying the puromycin drug resistance gene (pBabe puro) or a retrovirus carrying wild-type human c-myc or mutant human c-myceg, as well as puromycin resistance genes (pBabe Myc puro or pBabe MycEG puro). Following selection in medium containing puromycin, total cellular protein was isolated from individual drug-resistant colonies and assayed by immunoblot analysis for ectopic Myc and MycEG protein expression. Two random colonies demonstrating ectopic Myc protein expression, two colonies expressing MycEG protein, and two control colonies were expanded. Each of these six puromycin-resistant cell lines was subsequently infected with either a control retrovirus carrying the hygromycin resistance gene (pBabe hygro) or a retrovirus carrying wild-type human max or mutant human maxeg, as well as hygromycin resistance genes (pBabe Max hygro or pBabe MaxEG hygro). These double-infected cells were selected in medium containing both puromycin and hygromycin B sulfate, and drug-resistant colonies were pooled.
RNase protection. RNA was prepared by guanidinium isothiocyanate lysis and ultracentrifugation (22) . The RNase protection assay and probes have been described previously (36, 75) .
Immunoblot assay. Whole cell extracts were prepared from subconfluent, proliferating Rat-1 or NIH 3T3-10 cells by boiling cells in sample buffer containing 1 mM EDTA (56) . HL60 extracts have been described previously (36) . Proteins were resolved on denaturing sodium dodecyl sulfate-7.5 and 12% polyacrylamide gels to resolve the Myc and Max proteins, respectively, and electrotransferred onto polyvinylidene difluoride membranes (Millipore) in accordance with the manufacturer's recommendations. The membranes were blocked overnight in 10% nonfat milk (Carnation) in TBS-T (20 mM Tris [pH 7.5], 137 mM NaCl, 0.05% [vol/vol] Tween 20) and then washed for 0.5 h in TBS-T. The human c-Myc and MycEG proteins were detected by incubating membranes with a 1:5,000 dilution of polyclonal pan-Myc rabbit antiserum (a kind gift of T. Littlewood and G. Evan) in 1% milk-TBS-T for 1 h. The human Max and MaxEG proteins were visualized by using a 1:2,000 dilution of a polyclonal Max 2.1 rabbit antiserum (kind gift of T. Littlewood and G. Evan) under the above conditions. The membranes were washed as before and incubated with a 1:2,000 dilution of horseradish peroxidase-conjugated swine anti-rabbit antibody (Dako) in 1% milk-TBS-T for 0.5 h. Following washing, the signal was visualized by enhanced chemiluminescence (Amersham) with Kodak X-Omat autoradiography film.
RESULTS

Kinetics of Myc negative autoregulation in response to Myc-ER induction.
We have previously demonstrated specific downregulation of endogenous c-myc transcription in Rat-1 fibroblasts constitutively expressing ectopic Myc protein (36, 75, 76) . To further characterize the mechanism of Myc negative autoregulation in these Rat-1 cells, we studied the suppression kinetics of endogenous c-myc RNA levels in response to induction of the MycER fusion protein. The mycer gene is a chimera of human c-myc coding sequences and the estrogenbinding domain of the estrogen receptor (33) . In the absence of hormone, MycER protein is constitutively expressed at high levels in an inactive state. Addition of ␤-estradiol or the estrogen antagonist OH-T results in rapid activation of the MycER protein.
Rat-1 cells stably expressing MycER (Rat-1 MycER) were grown to confluency in PR Ϫ medium supplemented with 10% CTS and then rendered quiescent by incubation in PR Ϫ medium plus 0.1% CTS for 48 h. Cells were either left untreated (0 h) or treated with 100 nM ␤-estradiol or 100 nM OH-T to induce MycER activity. Cells were harvested at 0.5, 1, 2, 6, 12, 18, and 24 h following MycER induction, and total cellular RNA was prepared and assayed by RNase protection for endogenous rat c-myc expression and rat glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression as an RNA loading control. Similar experiments were conducted with subconfluent, proliferating Rat-1 MycER fibroblasts and with Rat-1 cells expressing a mutant MycER protein (Rat-1 ⌬MycER). This ⌬MycER fusion protein contains a deletion of Myc amino acids 106 to 143, a region encompassing the conserved MbII domain and critical for the autosuppression (76), cotransformation (97), G 1 -to-S phase progression (26, 33) , apoptosis (35) , and differentiation-blocking (38) activities of Myc.
In Rat-1 cells, both c-myc P1 and P2 promoters are active and similarly responsive; however, most transcripts initiate at the latter site (75) . Basal levels of endogenous rat c-myc P2-initiated RNA molecules were clearly evident in both untreated Rat-1 ⌬MycER and Rat-1 MycER cells ( Fig. 1A and B, lanes 1 and 9). Treatment of Rat-1 ⌬MycER cells with ␤-estradiol had no effect on steady-state levels of rat c-myc P2 transcripts throughout the assay (Fig. 1A, lanes 1 to 8) . However, activation of MycER by ␤-estradiol resulted in a clear decrease in endogenous rat c-myc P2 RNA levels (Fig. 1A , lanes 9 to 16). This suppression was first evident 2 h following addition of ␤-estradiol, reached a maximum by 12 h, and continued in the presence of activated MycER. In contrast, endogenous rat GAPDH RNA levels remained unresponsive to either ⌬MycER or MycER activation (Fig. 1) . Furthermore, both quiescent and proliferating Rat-1 ⌬MycER and MycER cells demonstrated similar responses to ␤-estradiol treatment with regard to P1-and P2-initiated transcripts (data not shown).
The MycER chimera contains a weak transcription activation domain (TAD) in the estrogen-binding motif (107) which may influence Myc function (95) . To demonstrate that sup- pression of c-myc RNA levels results solely from ectopic expression of Myc and not Myc in combination with the estrogen receptor TAD, we repeated the time course experiment with Rat-1 ⌬MycER and MycER cells by using OH-T as the effector. Unlike ␤-estradiol, OH-T does not activate the estrogen receptor TAD of the MycER protein (14, 27) . Once again, steady-state levels of rat c-myc RNA molecules remained constant in Rat-1 ⌬MycER cells during OH-T treatment (Fig. 1B,  lanes 1 to 8) . Furthermore, we found that OH-T treatment of MycER cells elicited a suppression of c-myc P2 RNA levels identical to that seen following ␤-estradiol treatment (Fig. 1B , lanes 9 to 16). A similar pattern of suppression kinetics was observed in Rat-1 MycER TM cells upon OH-T activation of the MycER TM fusion protein (data not shown). MycER TM is identical to MycER except for a functional mutation within the estrogen receptor TAD (61); thus, this element does not contribute to the suppressive activity of the MycER fusion protein. Therefore, endogenous c-myc RNA levels can be suppressed in Rat-1 cells by induction of Myc activity and this suppression is evident at 2 h following induction.
Wild-type but not mutant Myc protein can suppress transcription from the human c-myc P2 minimal promoter in Rat-1 cells. A complex array of positive and negative regulatory elements and transcription factor-binding sites have been mapped within the c-myc promoter. To identify which of these regions contribute to the Myc autosuppression mechanism, we tested several human c-myc promoter fragments in Rat-1 ⌬Myc-ER and MycER fibroblasts. The advantages of using Rat-1 fibroblasts stably expressing conditional MycER protein far outweigh introduction of the effector by transient transfection. The MycER system ensures that constant physiological Myc protein levels are delivered equally to all cells. In addition, this approach minimizes competitive squelching that might result from transient introduction of strong heterologous promoters present in mammalian expression vectors. Moreover, it allows the effect of Myc expression on both exogenous and endogenous c-myc promoters to be directly compared. A 2.5-kb HindIII-BamHI fragment of the human c-myc promoter, from nucleotides Ϫ2502 to ϩ34 relative to P2, was subcloned into the pGL2-basic reporter plasmid to promote expression of the firefly luciferase gene (HBM-Luc) ( Fig. 2A) . Previous experiments have shown that Myc autosuppression is mediated via suppression of transcription initiation, not elongation (24, 41, 75) ; therefore, to focus our attention on this aspect of transcriptional control, sequences in exon I and intron I which mediate elongation attenuation were not included. Two additional fragments were created by terminal deletion from the 5Ј end of HBM-Luc: a 502-bp fragment from Ϫ467 to ϩ34 (SNM-Luc) and a 142-bp fragment from Ϫ107 to ϩ34 (XNMLuc). The latter construct retains only minimal sequences required for correct transcription initiation from the P2 promoter (59, 100) ( Fig. 2A) .
Rat-1 cells demonstrate poor uptake of external DNA when grown in charcoal-treated serum; therefore, to augment transfection efficiencies, transfections were performed in the presence of calf serum. A reporter plasmid and a control plasmid expressing the lacZ gene from a cytomegalovirus promoter (pCMV-␤gal; a kind gift of T. Lee and E. Ziff) were transfected by calcium phosphate precipitation into Rat-1 MycER and ⌬MycER cells. Following transfection, the cells were incubated in PR Ϫ medium containing 10% CTS to allow inactivation of MycER and left untreated (0 nM) or treated with 1 or 100 nM OH-T to sustain MycER activity. At 24 h postinduction, cytosol extracts were prepared from both control and OH-T-treated cells and luciferase and ␤-galactosidase activities were assayed.
All three human c-myc promoter fragments demonstrated readily detectable basal-level activity in both Rat-1 MycER and ⌬MycER cells (Fig. 2B and C) . Basal transcription levels of the SNM-Luc construct were consistently higher than those observed for the other constructs due to the removal of known negative regulatory elements at positions Ϫ782 to Ϫ581 and Ϫ517 to Ϫ492 (23, 99) . Induction of ⌬MycER had no effect on basal-level transcription of any c-myc promoter fragment tested (Fig. 2C) . However, induction of MycER suppressed HBM-Luc promoter activity approximately four-to fivefold, relative to basal levels, to a minimum transcription level beyond which no further suppression could be obtained (Fig. 2B) . A similar four-to sevenfold suppression was seen with both the XNM-Luc and SNM-Luc fragments, respectively, and both constructs were also fully repressed to the minimum transcription level. The increase in fold suppression observed in the SNM-Luc construct is most likely the result of higher basallevel expression, as the minimum transcription level did not differ from that of the other constructs. In both Rat-1 ⌬MycER and MycER cells, treatment with OH-T had no effect on transcription from the pCMV-␤gal control plasmid in this and all of the subsequent assays described, indicating that the cytomegalovirus promoter is not regulated by Myc (Fig. 2D and data not shown). Thus, MycER protein can suppress transcription from a heterologous human c-myc promoter in Rat-1 cells. Remarkably, the cis elements required for this response are contained completely within the minimal sequences required for transcription from the P2 promoter.
As shown for negative autoregulation of the endogenous c-myc gene (Fig. 1) , equivalent degrees of suppression of the XNM-Luc promoter fragment were recorded upon treatment of Rat-1 MycER cells with either ␤-estradiol or OH-T, indicating no contribution of the estrogen receptor TAD (Fig. 2E) . Furthermore, the cis (E) and trans (Z) isoforms of OH-T were equal in biological activity at their respective effective doses.
Suppression of c-myc P2 minimal promoter activity is responsive to cellular concentrations of active MycER protein and follows kinetics similar to those of suppression of the endogenous c-myc gene. The inability of the ⌬MycER protein, which lacks an essential Myc autosuppression domain, to downregulate activity of human c-myc promoter fragments suggests that our transfection assay reflects Myc suppression of the endogenous c-myc gene. To explore this more fully, we characterized several aspects of P2 minimal promoter suppression in response to ectopic Myc expression in comparison to Myc downregulation of endogenous c-myc mRNA levels. In Rat-1 fibroblasts, Myc negative autoregulation operates at physiological Myc protein levels, and the degree of suppression of endogenous c-myc transcription is proportional to the Myc protein concentration (75) . To assay the dose responsiveness of the P2 minimal promoter to MycER induction, XNM-Luc was transfected into Rat-1 ⌬MycER and MycER cells as described above. Cells were either left untreated (0 nM) or treated with 0.1, 0.3, 1, 3, 10, 30, 100, 200, or 400 nM OH-T for 24 h, and then luciferase and ␤-galactosidase activities were assayed. As before, extracts from Rat-1 ⌬MycER cells showed no reduction in relative luciferase activity, even at 400 nM OH-T (Fig. 3A) . In contrast, MycER activation resulted in three-to fourfold suppression of luciferase activity. This suppression was proportional to the concentration of OH-T added to the cells and reached a maximum level at 100 nM OH-T (Fig. 3A) . Therefore, MycER suppression of the c-myc P2 promoter, like suppression occurring at the endogenous c-myc gene, is dependent on functional Myc protein concentrations.
We next examined the kinetics of c-myc P2 minimal promoter suppression in response to MycER activation. XNM- Luc-transfected Rat-1 ⌬MycER and MycER cells were either left untreated (0 h) or treated with 200 nM OH-T for 0.5, 1, 2, 6, 12, 18, or 24 h prior to simultaneous harvesting and assaying at time zero. Once again, c-myc P2 promoter transcription remained refractory to induction of ⌬MycER and was gradually suppressed upon activation of MycER (Fig. 3B) . Significant downregulation of XNM-Luc activity first occurred between 6 and 12 h following OH-T treatment and reached threefold after 24 h. Taking into account that the protein half-life of luciferase in mammalian cells is approximately 3 to 6 h (101), the kinetics of XNM-Luc suppression by MycER strongly resembles the suppression pattern of endogenous rat c-myc RNA levels (compare Fig. 1 with 3B ). These data indicate that our promoter assay shares two characteristics with physiological suppression of endogenous c-myc RNA levels: dependency on the Myc protein concentration and the pattern of suppression kinetics in response to Myc induction.
Domains of the human c-Myc protein involved in c-myc P2 minimal promoter suppression correspond to those required for suppression of the endogenous c-myc gene. We wondered (78) . To test the relevance of these regions to c-myc P2 promoter transcription suppression, Rat-1 cell lines stably and constitutively expressing various human c-Myc protein deletion and insertion mutants were transfected with XNM-Luc and assayed for promoter activity. All cell lines demonstrated ectopic Myc protein expression by immunoblot analysis of whole cell extracts (data not shown), as previously reported (76) . Each cell line was seeded at the same cell density in PR ϩ medium containing 10% fetal bovine serum and transfected on the following day with XNM-Luc along with the pCMV-␤gal control plasmid. Following transfection, the cells were incubated for 24 h and harvested, and then luciferase and ␤-galactosidase activities were assayed. This system differs from the preceding assays in that the effector is human Myc protein rather than the MycER chimera and expression of the effector is constitutive, not inducible.
As before, transcription from the c-myc P2 minimal promoter was suppressed four-to fivefold in the presence of ectopic wild-type Myc protein compared with cells not expressing the ectopic Myc protein (Fig. 4 , Hu-c-Myc versus Control), further substantiating that this suppression is a Myc-specific effect and not influenced by the ER portion of the MycER fusion protein. Human c-Myc protein mutants ⌬41-53, In 105, and ⌬265-317 also suppressed XNM-Luc activity, although to a slightly lesser extent than the wild-type protein. Once again, ectopic expression of human c-Myc protein harboring a deletion of amino acids 106 to 143 had no effect on the basal level of c-myc P2 promoter transcription. In addition, disruption of the BR, HLH, or Zip domain by either deletion or insertion mutations completely abolished the ability of Myc to suppress transcription from the c-myc P2 promoter (Fig. 4, ⌬265-367 , ⌬371-412, In 373, ⌬414-433, and In 414). Interestingly, ectopic expression of one mutant, ⌬265-367, which removes the DNAbinding domain and nuclear localization sequences but retains the capacity to form heterodimers with Max, resulted in threefold activation of P2 promoter activity. Whether this apparent dominant negative effect is due to inefficient translocation to the nucleus or impaired DNA binding is not clear. These results provide further evidence that the c-myc P2 minimal promoter response to ectopic Myc expression mimics that of the endogenous c-myc gene. Furthermore, our data suggest that the Myc negative autoregulation mechanism differs from the mechanism by which Myc suppresses the cyclin D1 pro- moter, as independent domains of the Myc protein appear to be involved, and may be similar to the repression mechanism of the AdMLP.
Ectopic Myc expression does not suppress transcription of heterologous c-myc promoter fragments in a Myc autosuppression-dysfunctional NIH 3T3 cell line. Our observations that Myc suppression of c-myc P2 minimal promoter activity and Myc downregulation of endogenous c-myc promoter transcription require similar domains of the Myc protein, respond to the Myc protein concentration, and have similar patterns of kinetics suggest a functional similarity between these two responses. However, these data do not determine whether the two suppression events make use of the same mechanistic pathways and involve common cellular components. To address this question more directly, we transfected HBM-Luc, SNM-Luc, and XNM-Luc reporter constructs into the NIH 3T3-10 cell line in the presence or absence of a constitutively expressed v-myc gene. NIH 3T3-10 is a clonally derived population of NIH 3T3 cells isolated in our laboratory and differs from previously described NIH 3T3 cells with respect to the Myc autosuppression phenotype (24) . In particular, these cell lines have spontaneously acquired a mutation within one or more cellular trans-acting components of the Myc autosuppression pathway, such that ectopic Myc protein expression no longer suppresses basal levels of endogenous murine c-myc transcription (Fig.  5A) (75) .
Unlike Rat-1 fibroblasts, ectopic v-myc expression in NIH 3T3-10 cells had no effect on basal transcription levels from the HBM-Luc, SNM-Luc, or XNM-Luc promoter fragments (Fig.  5B) , even though ectopic v-myc was expressed at levels comparable to that found in Rat-1 cells (Fig. 5A and data not shown). Taken together, these results, in combination with data presented in Fig. 2, 3 , and 4, provide strong evidence that the mechanism of Myc suppression of heterologous c-myc promoters measured by our assay is the same mechanism as Myc suppression of the endogenous c-myc gene and that the region of the promoter which confers this Myc autosuppression activity maps to P2 minimal promoter sequences. The probe for endogenous c-myc was as described in the legend to Fig. 1 ; murine GAPDH transcripts were detected with a probe specific for mouse GAPDH sequences. Ectopic expression of v-gagmyc (v-myc) was detected with a probe specific for viral gag sequences of avian myelocytomatosis virus strain MC29. (B) Control NIH 3T3-10 fibroblasts (black bars) and NIH 3T3-10 fibroblasts stably expressing v-myc (white bars) were transfected with 3 g of reporter plasmid DNA plus 0.1 g of pCMV ␤-gal and assayed for relative luciferase activity. Results represent the average of two independent assays.
XhoI-NaeI fragment of the human c-myc P2 promoter contains a number of transcription regulatory elements which bind specific factors and negatively regulate c-myc transcription, including ME1a1, E2F/Ets, and the MBP-1-binding sites (Fig. 6A) .
To determine whether factor binding to any of these elements contributes to Myc negative autoregulation, we constructed, within the XNM-Luc reporter construct, point mutations in each of these motifs which have been previously shown to abrogate protein-DNA interactions and disrupt function (Table 1). These c-myc promoter mutant constructs were transfected into Rat-1 MycER and ⌬MycER cells and assayed for promoter responsiveness to MycER or ⌬MycER induction. In Rat-1 MycER cells, all promoter mutant constructs, with the exception of the ME1a1-2 mutant, demonstrated 4-to 5.5-fold repression of luciferase activity upon MycER induction relative to individual basal promoter activity, while no significant repression was detected when the constructs were transfected into Rat-1 ⌬MycER cells (Fig. 6B and C) . Mutation of the ME1a1 element eliminated basal promoter activity close to the minimum expression levels; however, even this reduced activity was still repressed twofold by MycER, indicating that this mutated promoter retains some responsiveness to the Myc protein.
Several recent investigations have shown that c-Myc at high concentrations represses transcription through promoter initiator (Inr) elements (58, 65, 78) . The c-myc P2 minimal promoter contains two adjacent sites, Inr-A and Inr-B, which conform to the Inr consensus sequence YYANTYY (30); however, primer extension experiments detected RNA molecules initiating only from the more 3Ј site (Fig. 6A, Inr-A) (91) . In the AdMLP Inr, which shares substantial homology with c-myc Inrs, mutation of residues Ϫ1 and Ϫ2 or ϩ2, ϩ3, and ϩ4 relative to the transcription start site reduced USF binding to Inr elements and abrogated Myc transcriptional repression through these sequences without significantly affecting basal transcription levels (58) . Based on these observations, we constructed analogous mutations within the putative c-myc P2 Inr(s) to determine whether these elements play a role in Myc autosuppression (Table 1) . Unlike suppression of the AdMLP, mutation of either Inr element did not affect P2 promoter suppression by MycER relative to the wild-type XNM-Luc promoter response ( Fig. 6B and C) . Our data suggest that the Myc protein may evoke suppression of the c-myc P2 minimal promoter independently of known promoter elements, including initiator sites.
Myc-Max association is required for Myc autosuppression.
We have previously demonstrated that the Myc autosuppression mechanism involves the Myc protein and at least one additional cellular factor (75) . Furthermore, the regions of the c-Myc protein required for Myc negative autoregulation include the BR-HLH-Zip domains (76) . Therefore, a likely candidate for a trans-acting cellular component of this autosuppression pathway is the Myc binding partner, Max. To determine whether Myc-Max complex formation is required for Myc autosuppression, the MycEG and MaxEG mutant proteins, along with their wild-type Myc and Max counterparts, were stably expressed in Rat-1 fibroblasts, either alone (Fig. 7 , lanes 4 to 9 and 14 to 15) or as heterologous pairs (Fig. 7, lanes 10 to 13  and 16 to 19 ). MycEG and MaxEG contain reciprocal amino acid substitutions within the Zip domains which alter the dimerization specificities of both proteins, such that MycEG interacts exclusively with MaxEG but not with cellular wildtype Max and, conversely, MaxEG forms heterodimers with MycEG but not endogenous cellular Myc (4). Previous exper- iments with these mutants in Rat-1 fibroblasts have shown that Myc-Max heterodimerization is required for Myc transformation activity (4), as well as G 1 -to-S phase cell cycle progression and Myc-induced apoptosis (6). Rat-1 fibroblasts in cell culture grow as a flat monolayer and exhibit contact inhibition at confluency (Fig. 8A) . Ectopic expression of Myc in these cells is accompanied by a distinct morphological change characterized by an increase in cell density, a decrease in average cell size, and increased apoptotic events (Fig. 8B) . In this experiment, constitutive, ectopic expression of the MycEG, Max, or MaxEG protein alone or MycEG in combination with wild-type Max had no visible effect on overall cell morphology compared with control cells (Fig. 8, compare panels C, D , G, and F with panel A, respectively). Cells expressing the wild-type Myc protein alone or in combination with the Max or MaxEG protein displayed the characteristic Myc phenotype (Fig. 8B, E, and H, respectively) . Interestingly, Rat-1 cells expressing ectopic MycEG together with MaxEG also adopted this Myc phenotype (Fig. 8I) , demonstrating functional in vivo interaction between the MycEG and MaxEG proteins.
Total cellular RNA was harvested from subconfluent, proliferating cells and assayed by RNase protection for endogenous c-myc RNA levels by using a rat-specific c-myc exon I probe. Basal levels of P2-initiated endogenous rat c-myc transcripts were readily detected in control Rat-1 fibroblasts (Fig.  9, lanes 1 and 2) and were suppressed in cells expressing the ectopic, wild-type human c-Myc protein, either alone (Fig. 9 , lanes 3 and 4) or in combination with the wild-type Max or MaxEG protein (Fig. 9, lanes 9 and 10 and lanes 15 and 16,  respectively) . Ectopic expression of mutant MycEG alone did not result in a significant change in rat c-myc RNA levels (Fig.  9, lanes 5 and 6) . Likewise, there was little overall change from basal c-myc levels in Rat-1 cells constitutively expressing either the wild-type Max or MaxEG protein alone (Fig. 9, lanes 7 and  8 and lanes 13 and 14, respectively) . Cells expressing MycEG along with the wild-type Max protein demonstrated a marginal suppression of endogenous rat c-myc RNA levels (Fig. 9, lanes  11 and 12) , whereas c-myc RNA levels were fully suppressed in Rat-1 cells expressing the MycEG mutant together with MaxEG (Fig. 9, lanes 17 and 18) . The partial suppression detectable in Rat-1 MycEG-Max cells may result from lowlevel functional interaction between the MycEG and Max proteins (4). Thus, Myc-Max association is obligatory for Myc autosuppression. VOL. 17, 1997 Myc therefore, Myc suppression of c-myc P2 transcription is an active mechanism and does not result from transactivation domain competition. Finally, 2.5-kb and truncated c-myc promoter fragments remained unresponsive to ectopic Myc expression when tested in a variant NIH 3T3 cell line that has acquired an inactivating mutation in the Myc autosuppression pathway. Nature of the Myc autosuppression response element. Myc autosuppression is a global homeostatic mechanism which regulates transcription from both c-myc P1 and P2 promoter sites and is functional in primary and many immortalized cell lines but dysfunctional in tumorigenic and transformed cell lines (36, 41, 75) . Thus, the cis components of this pathway must be capable of influencing c-myc transcription from both promoters and in a wide range of nontransformed cell types. To affect both P1 and P2 transcription, the candidate cis element would either be common to both promoters, lie between P1 and P2 and function bidirectionally, or invoke promoter-proximal pausing at P2 (55), thereby interfering with elongation of P1 transcripts. Several previously defined regulatory elements involved in the downregulation of c-myc expression lie within the 142-bp XhoI-NaeI P2 fragment we have defined as critical for Myc negative autoregulation. These potential mediators of the Myc autosuppression response include ME1a1, E2, MBP-1, and Inr elements.
The role of ME1a1 as an important regulator of c-myc transcription initiation and elongation is well documented (7, 31, 44, 71) . Indeed, we have found that mutations within this element drastically reduce c-myc basal transcription levels. At least two cellular proteins bind to this region: the zinc finger protein MAZ (19) and the human Cut-like homeodomain protein (hCut) (32) . While the consequence of MAZ interaction with the c-myc promoter remains to be determined, hCut acts to repress c-myc P2 promoter transcription through a mechanism which is dependent on both ME1a1 and downstream exon 1 sequences. It has been suggested, however, that hCut can demonstrate relaxed DNA-binding sequence specificity; therefore, it is possible that in the absence of preferred sequences, hCut may still interact with the c-myc promoter through additional sites (47) . Our ME1a1 mutant promoter constructs lacking exon I sequences downstream of the P2 initiator remained somewhat responsive to suppression by Myc protein. The degree of suppression was significantly less than that observed on the wild-type promoter construct; however, this appears to result from compromised basal transcription levels. At this point, involvement of ME1a1 sequences and hCut in the Myc autosuppression mechanism requires further attention and is currently under investigation.
Binding of E2F to the E2 element within the context of the c-myc promoter is critical for E1A-, v-Abl-, and serum-induced c-myc transcription activation (48, 100, 110) . This enhanced expression may be negatively modulated in part by members of the retinoblastoma gene family. pRb-E2F complex formation sequesters E2F and represses transcription of E2-containing promoters, including the c-myc promoter (45, 108) . Likewise, a decrease in p107-E2F complexes at the c-myc E2 binding site and an increase in free E2F accompany human granulocytemacrophage colony-stimulating factor-or murine interleukin-3-induced c-myc activation (105) . We report here that the c-myc E2 promoter element is dispensable with regard to Myc negative autoregulation. Furthermore, we have observed that the Myc autosuppression mechanism is intact in primary and immortalized RB1-negative cell lines (68) , suggesting that proteins other than E2F and pRb family members constitute the major components of the Myc negative autoregulatory pathway.
MBP-1 is a proline-rich DNA-binding protein which interacts with a specific site immediately upstream of and overlapping c-myc P2 TATA box sequences (83) . Biologically, ectopic expression of MBP-1 results in extensive death of NIH 3T3 fibroblasts, reduced basement membrane invasion potential and anchorage-independent growth in human breast carcinoma cells, and suppression of tumor formation in nude mice (84, 85) . These growth suppressive effects may be linked to the ability of MBP-1 to negatively regulate transcription from the c-myc P2 promoter; however, the molecular mechanism of MBP-1 transcription repression is unknown (83) . In this study, we showed that a mutation within the MBP-1-binding site of the human c-myc P2 promoter which abolishes MBP-1 interaction with DNA does not disrupt Myc suppression of c-myc FIG. 9 . Association of Myc and Max proteins is required for Myc negative autoregulation in Rat-1 fibroblasts. RNase protection assay of 10 g of RNA from subconfluent, proliferating Rat-1 cells stably expressing combinations of the Myc, Max, MycEG, and/or MaxEG proteins and described in Fig. 7 and 8 . Two independently derived cell lines from each group were analyzed. The probes used for the assay are described in Fig. 1. transcription, suggesting that MBP-1 is not involved in Myc autosuppression.
Accumulating evidence suggests that c-Myc may repress transcription initiation through Inr elements. The growing list of promoters which demonstrate this phenomenon includes the AdMLP and the c/EBP␣, albumin, cyclin D1, 5, and TdT promoters (58, 65, 78) . The c-myc P2 promoter contains two tandem Inr consensus sequences similar to those found within the AdMLP and the albumin, TdT, and cyclin D1 promoters. In contrast to the above reports, we found that several different mutations within the c-myc P2 Inr element(s) in the context of the P2 minimal promoter had no effect on Myc protein downregulation of c-myc transcription. Although the Myc protein domains required to suppress the c-myc promoter overlap those required for downregulation of the AdMLP, results from our promoter analysis suggest that these two suppression responses involve distinct mechanisms.
Our data imply that loss of any one of the above regulatory motifs in the context of the P2 minimal promoter is insufficient to abrogate the Myc negative autoregulation pathway. While our promoter assay accurately reflects the Myc autosuppression mechanism at numerous levels, it remains possible that differences in heterochromatin structure or promoter context between the episomal P2 minimal promoter and the endogenous c-myc promoter may influence protein binding and activity at these sites. Conceivably, two or more of these elements may function together in Myc autosuppression such that a combination of mutations would be required to disrupt this pathway. Alternatively, the critical element may be a novel sequence or another known protein-binding sequence within the XhoI-NaeI fragment, such as Sp1 or TATA elements. Finally, autosuppression of the c-myc promoter may occur independently of a specific DNA element, involving DNA topology (53) or, like repression mediated by the Msx-1 homeodomain protein (21) , interaction with the general transcription machinery.
An obligatory role for Max in Myc autosuppression. We demonstrate in this report that the Myc binding partner, Max, constitutes an essential trans-acting component of the Myc negative autoregulation mechanism. This finding evokes the question of whether Myc-Max heterodimerization is required for all biological activities of the c-Myc protein. Several other cellular proteins interact with the c-Myc carboxyl terminus in vitro (TFII-I and YY-1) (90, 94) and in vivo (AP-2) (39) and, in some instances, can compete with Max for Myc binding. However, sedimentation and coimmunoprecipitation experiments with cell lysates reveal that nearly all c-Myc molecules preferentially exist in preformed heterodimeric complexes with Max (60). This is in keeping with biological data showing that c-Myc-Max association is obligatory for the G 1 -to-S phase cell cycle progression, Myc-induced apoptosis, and cellular transformation activities of the Myc protein (4, 6), as well as for Myc-mediated transcriptional activation (5) . Max also has the ability to form heterodimeric complexes with L-myc and N-myc (73, 109) and is required for oncogenic transformation by the latter (73) . The role of Max in Myc downregulation of the AdMLP and the c/EBP␣, 5, and TdT promoters has not been directly addressed but may be important, as Zip and/or HLH domains of the c-Myc protein are required for this suppression (58, 65) . On the contrary, Myc suppression of cyclin D1 transcription has been reported to occur independently of Myc and Max association (78) . Interestingly, the c-Myc protein domains required for cyclin D1 suppression diverge from those which are crucial to Myc oncogenic, proliferative, apoptotic, and negative autoregulatory activities. We have also shown that Myc repression of cyclin D1 differs functionally from Myc autosuppression (68), indicating that Myc can repress specific gene transcription by at least two distinct mechanisms. Our present findings are consistent with evidence supporting an obligatory requirement for Myc-Max heterodimerization in key physiological c-Myc functions, including Myc autosuppression.
Binding of Myc-Max heterodimers to specific CACGTG sites resulting in transcription activation of promoters possessing these motifs is well documented (5, 15, 17, 37, 43, 80) . Myc-Max transcription activation through the CACGTG motif operates over a distance of 1.7 kb in a manner independent of element position and orientation. However, no Myc-Max-specific E box elements are found within this distance from the c-myc P1 or P2 promoter or within the 142-bp XhoI-NaeI promoter fragment we have defined as being critical to Myc autosuppression. Furthermore, affinity capture assays failed to detect Myc-Max complexes on Xenopus c-myc genomic DNA (20) . Our data show that Myc-Max heterodimerization is required for Myc autosuppression, yet this mechanism clearly does not involve Myc-Max binding to a CACGTG DNA element within the c-myc promoter.
Models for the Myc negative autoregulation mechanism. It has been proposed that Myc autosuppression may result from Myc inhibition of YY-1 activity (94); however, this is difficult to reconcile with data presented in this report demonstrating mandatory Myc-Max heterodimerization in Myc autosuppression. YY-1 is a multifunctional, zinc finger DNA-binding protein that interacts with the carboxyl terminus of the c-Myc protein. Furthermore, expression of YY-1 activates c-myc P1 and P2-initiated transcription in murine erythroleukemia cells and P3X plasmacytomas (87, 94) . Approximately half of this activity is contained within the P1 and P2 minimal promoters but appears to be independent of any DNA-binding site. Cotransfection of YY-1 and Myc in P3X cells strongly inhibits YY-1-mediated activation of a c-myc promoter-luciferase reporter construct, suggesting a potential mechanism for Myc negative autoregulation. However, Myc and YY-1 fail to form a ternary complex with a glutathione S-transferase-Max fusion protein, and furthermore, the presence of Max abolishes Myc binding to glutathione S-transferase-YY1 (94) . Our results indicate that Myc autosuppression requires Myc-Max heterodimerization, and this precludes Myc interference of YY-1 activation by direct association of the latter two proteins.
Experimental data presented in this report and by others (41, 102) support both an indirect function and a direct function for Myc-Max heterodimers in the Myc autosuppression mechanism. In the indirect model, Myc-Max heterodimers bind to specific E-box elements within the promoter of a third gene to activate transcription. The protein product of this gene then suppresses c-myc basal transcription either through interaction with the general transcription apparatus or elsewhere on the P2 minimal promoter. An obvious potential candidate for this third gene is the p53 tumor suppressor. p53 expression is upregulated by Myc in certain cell lines and can interact with basal transcription machinery to repress c-myc transcription. However, we have observed that p53 was not regulated by Myc in our Rat-1 cells (68a). Moreover, Myc autosuppression remained intact in Rat-1 fibroblasts stably expressing simian virus 40 large T antigen or a mutant p53 allele (68a). Therefore, Myc negative autoregulation does not function through p53 but may involve a novel protein which acts in a manner analogous to that of p53. We are currently investigating this hypothesis.
Interestingly, moderate suppression of c-myc RNA expression by Myc is retained in cycloheximide-treated Rat-1 cells and Epstein-Barr virus-immortalized human lymphoblasts, suggesting that the Myc autosuppression mechanism involves a direct component (36a, 41) . This direct model proposes that the critical function of Myc-Max heterodimerization is to stabilize protein-protein interactions, allowing Myc-Max heterodimers to form ternary complexes which may or may not be tethered to DNA or the nuclear matrix. In this model, MycMax heterodimers interact with the basal transcription machinery to actively block transcription initiation or sequester an essential factor and prevent assembly of a functional transcription initiation complex. Indeed, transcription factors Fos and Jun can both transactivate via AP-1 sites and inhibit glucocorticoid receptor transactivation through ternary complex formation (93, 112) . Ternary complex formation is exhibited by two other members of the Myc superfamily, the Mad and Mxi proteins, indicating that Max binding to HLH-Zip regions does not necessarily prohibit the binding of other factors (8, 92) . Moreover, the TBP, p107, and ␣-tubulin proteins all bind to the c-Myc protein amino terminus in vivo (3, 9, 42, 64) , but it remains unclear whether Max is involved in these associations, as Myc-Max ternary complexes have not been described. Apart from TBP, Myc has also been shown to interact in vitro with the TFII-I initiator-binding protein and bind to the AdMLP Inr sequence (90) ; however, the presence of Max within this protein-DNA complex has not been thoroughly investigated. Furthermore, the c-Myc and Max proteins were detected in complexes forming on 5 and TdT core promoter sequences, and c-Myc expression in pre-B cells repressed transcription of luciferase reporter constructs containing these initiator elements (65) . These reports and data presented here suggest that Myc can interact with components of the basal transcription machinery and that this interaction is involved in Myc downregulation of gene expression.
Myc negative autoregulation provides a strong physiological model system to examine the molecular mechanisms of Myc transcriptional repression. Unraveling the mechanism of this homeostatic regulatory pathway will be facilitated by identifying other cellular targets of Myc activation and repression, by understanding the molecular and biological activities of the structurally and functionally conserved Myc protein domains, and by identifying additional Myc-binding proteins.
